Skip to main content

Whitehawk Therapeutics, Inc.

For the period ended Jun 11, 2025. Filed Apr 28, 2025.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Jun 11, 2025 · Filed Apr 28, 2025

WHWK$3.13+3.6%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934

Filed by the Registrantx

Filed by a party other than the Registranto

Check the appropriate box:

oPreliminary Proxy Statement
oConfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
xDefinitive Proxy Statement
oDefinitive Additional Materials
oSoliciting Material under §240.14a-12

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

xNo fee required.
oFee paid previously with preliminary materials.
oFee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

April 28, 2025

To the Stockholders of Whitehawk Therapeutics, Inc.:

You are cordially invited to attend the 2025 Annual Meeting of Stockholders (the "Annual Meeting") of Whitehawk Therapeutics, Inc. (the “Company”), which will be held online on Wednesday, June 11, 2025 at 10:00 a.m. Pacific Time via webcast atwww.virtualshareholdermeeting.com/WHWK2025. The Annual Meeting will be a completely virtual meeting which will be conducted via live webcast.

Details regarding admission to the meeting and the business to be conducted are more fully described in the accompanying Notice of Annual Meeting and Proxy Statement.

At this Annual Meeting, the agenda includes:

  1. To elect three Class II directors to serve on the Company’s board of directors until the Company’s 2028 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier resignation, death or removal;

  2. To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the “Executive Compensation” section of the proxy statement;

  3. To ratify the appointment of BDO USA, P.C. as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2025; and

  4. To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.

Whether or not you attend the Annual Meeting, it is important that your shares be represented and voted at the meeting. Therefore, we urge you to promptly vote and submit your proxy via the Internet, by phone or, if you requested printed copies of the proxy materials by mail, by signing, dating and returning the enclosed proxy card in the enclosed envelope. If you decide to attend the Annual Meeting, you will be able to change your vote, revoke your proxy or vote electronically at the Annual Meeting.

We hope that you will join us virtually on June 11, 2025. Your investment and continuing interest in the Company are very much appreciated.

Sincerely yours,

/s/ David Lennon

David Lennon, Ph.D.

President & Chief Executive Officer

/s/ Caley Castelein

Caley Castelein, M.D.

Chairman of the Board

2 Headquarters Plaza, East Building, 11th Floor

Morristown, New Jersey 07960

NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS

To Be Held Online on Wednesday, June 11, 2025 at

www.virtualshareholdermeeting.com/WHWK2025

Notice is hereby given that the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Whitehawk Therapeutics, Inc. (the “Company”), will be held online on June 11, 2025 at 10:00 a.m. Pacific Time. The Annual Meeting will be a virtual meeting, which will be conducted via live webcast. You will be able to attend the meeting virtually via the Internet, vote your shares electronically and submit your questions during the Annual Meeting via the Internet atwww.virtualshareholdermeeting.com/WHWK2025. You will need your 16-digit control number, which is located on the Notice of Internet Availability of Proxy Materials (the “Notice of Availability”) that you received in the mail, on your proxy card or in the instructions accompanying your proxy materials, to attend the Annual Meeting.

The purpose of the Annual Meeting is the following:

  1. To elect three Class II directors to serve on the Company’s board of directors until the Company’s 2028 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier resignation, death or removal;

  2. To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the “Executive Compensation” section of the proxy statement;

  3. To ratify the appointment of BDO USA, P.C. as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2025; and

  4. To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.

Stockholders of record at the close of business on April 17, 2025, the record date for the Annual Meeting (the “Record Date”), are entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement of the Annual Meeting. Further information regarding voting rights and matters to be voted upon is presented in the accompanying proxy statement.

To participate in the Annual Meeting, you will be required to enter the 16-digit control number provided in the Notice of Availability or the proxy card atwww.virtualshareholdermeeting.com/WHWK2025 and beneficial owners of shares held in street name must additionally follow the instructions provided by the broker, bank or other nominee that holds their shares. Please see the “General Information” section of the Proxy Statement that accompanies this notice for more details regarding the logistics of the virtual Annual Meeting, including the ability of stockholders to submit questions during the Annual Meeting, and technical details and support related to accessing the virtual platform. You will not be able to attend the Annual Meeting in person.

YOUR VOTE IS IMPORTANT. Whether or not you are able to attend the Annual Meeting, it is important that your shares be represented. To ensure that your vote is recorded promptly, please vote as soon as possible, even if you plan to attend the Annual Meeting, by submitting your proxy over the Internet or by telephone as described in the instructions included in the Notice of Availability or by signing, dating and returning the proxy card. Returning the proxy does not deprive you of your right to attend the Annual Meeting and to vote your shares at the Annual Meeting.

Important Notice Regarding the Availability of Proxy Material for the Annual Meeting to be held on June 11, 2025. Our proxy statement and Annual Report to the Stockholders are being made available on or about April 28, 2025 atwww.proxyvote.com. We are providing access to our proxy materials over the Internet under the “notice and access” rules adopted by the Securities and Exchange Commission.

By order of the Board of Directors,

/s/ David Lennon

David Lennon, Ph.D.

President & Chief Executive Officer

TABLE OF CONTENTS

Page
GENERAL INFORMATION1
PROPOSAL ONE – ELECTION OF DIRECTORS6
CORPORATE GOVERNANCE11
DIRECTOR COMPENSATION16
EXECUTIVE COMPENSATION18
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT29
CERTAIN RELATIONSHIPS AND RELATED-PERSON TRANSACTIONS, AND DIRECTOR INDEPENDENCE33
PROPOSAL TWO – ADVISORY VOTE ON EXECUTIVE COMPENSATION35
PROPOSAL THREE – RATIFICATION OF THE APPOINTMENT OF OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM36
TRANSACTION OF OTHER BUSINESS39
ADDITIONAL INFORMATION39
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.